{"id":"AGY-FED-HEALTH-OTHER-025","kind":"context","level":"federal","jurisdiction":"United States (federal); Department of Health and Human Services, Substance Abuse and Mental Health Services Administration","state":"","metro":"","industry":"","agency":"FED-HEALTH-OTHER","eco":"","issuer":"SAMHSA, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies","authority":"42 C.F.R. 8.11(h) (exemptions from part 8 standards), 8.12(i) (unsupervised or take-home use)","instrument":"FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency","title":"FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency","dateIssued":"2020-04-21","effective":"2020-04-21","end":"Through the public health emergency (take-home exemption extended Nov. 18, 2021 and made permanent Apr. 2, 2024)","startDate":"2020-04-21","endDate":"2021-11-18","quarters":["2020Q2","2020Q3","2020Q4","2021Q1","2021Q2","2021Q3"],"types":["HC","OTHER"],"addressees":["opioid treatment programs","DATA-waived practitioners","State opioid treatment authorities"],"clause":"Under the current national health emergency, OTPs can provide medication under blanket exception: up to 14 doses for clinically less stable patients and 28 doses for clinically stable patients (clinical stability and ability to safely manage medication must be determined by the clinical team and documented in the patient\u0027s medical record).","enforcement":"Conditions of OTP certification under 42 C.F.R. 8.11-8.14","functions":["CL clinical dosing","FD scheduling (fewer daily visits)","CB patients"],"notes":"","sourceUrl":"https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf","snapshot":"","fileExists":true,"fileBytes":206622,"grade":"primary","character":"context","description":"","collection":"AGY-FED-HEALTH-OTHER","url":"/library/AGY-FED-HEALTH-OTHER-025","exhibitUrl":"/exhibit/AGY-FED-HEALTH-OTHER-025","citation":"SAMHSA, Center for Substance Abuse Treatment, Division of Pharmacologic Therapies, FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency (Apr. 21, 2020) (Ex. AGY-FED-HEALTH-OTHER-025)","stateName":"","related":[]}